<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs001050.v1.p1" parentStudy="phs001050.v1.p1" createDate="2015-12-22" modDate="2016-01-21">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigators</td><td>Matthew Goetz, MD</td><td>Mayo Clinic, Rochester, MN, USA</td></tr>
		<tr><td>Principal Investigators</td><td>Judy Boughey, MD</td><td>Mayo Clinic, Rochester, MN, USA</td></tr>
		<tr><td>Funding Sources</td><td>U10GM 61388-15</td><td>Pharmacogenomics Research Network, USA</td></tr>
		<tr><td>Funding Sources</td><td>CA15083-40A2</td><td>Mayo Clinic Cancer Center, USA</td></tr>
		<tr><td>Funding Sources</td><td>P50CA 116201-9</td><td>Mayo Clinic Breast SPORE, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Breast Cancer Genome Guided Therapy Study (BEAUTY)</StudyNameEntrez>
	<StudyNameReportPage>Breast Cancer Genome Guided Therapy Study (BEAUTY)</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case Set</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>The Breast Cancer Genome Guided Therapy Study (BEAUTY) is a prospective neoadjuvant clinical study enrolling 140 women with Stage I-III breast cancer. The goals of this study were to 1) perform comprehensive sequencing of germline and tumor tissues (exome and RNA seq), 2) identify genomic alterations and perturbed pathways associated with response/resistance to standard chemotherapy, and 3) develop patient-derived xenograft (PDX) for testing of therapeutic regimens chosen on the basis of alterations identified by genetic sequencing.</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p><b><i>Inclusion Criteria</i>:</b><br/> 1) Age &#8805;18 years.<br/> 2) Histological confirmation of invasive breast cancer. <br/> 3) Confirmation of breast cancer lesion &#8805; 1.5 cm in size by any clinical (physical examination measurement) or radiographic criteria (mammogram, ultrasound or MRI) in the ipsilateral breast. Note: Benign breast disease, LCIS or DCIS in the contralateral breast is allowed. Contralateral invasive breast cancer is allowed if disease is of clinically lower stage and the higher stage lesion will be the study lesion for all biopsies and tissue samples.<br/> 4) Provide informed written consent. <br/> 5) Willing to return to Mayo Clinic in Rochester, MN, Mayo Clinic in Arizona, or Mayo Clinic in Florida for imaging correlative, surgery, and follow-up.<br/> 6) Willing to provide blood samples for correlative research purposes. <br/> 7) Willing to provide tissue samples for correlative research purposes. <br/> 8) ECOG Performance Status &#8804; 2. <br/> <b><i>Exclusion Criteria</i>:</b><br/> 1) Disease in axilla only <br/> 2) Receiving any investigational agent which would be considered as a treatment for the primary neoplasm. <br/> 3) Other active malignancy &#8804; 5 years prior to registration. EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix. Note: If there is a history or prior malignancy, they must not be receiving any other treatment for their cancer. <br/> 4) Patients who are not planning to receive neoadjuvant chemotherapy. <br/> 5) Biopsy proven Stage IV disease. <br/> 6) Patients who are pregnant or nursing.<br/> </p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Breast Neoplasms"/>
		<Disease vocab_source="MESH" vocab_term="Carcinoma, Ductal, Breast"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigators">
			<AttName>Matthew Goetz, MD</AttName>
			<Institution>Mayo Clinic, Rochester, MN, USA</Institution>
		</Header>
		<Header title="Principal Investigators">
			<AttName>Judy Boughey, MD</AttName>
			<Institution>Mayo Clinic, Rochester, MN, USA</Institution>
		</Header>
		<Header title="Funding Sources">
			<AttName>U10GM 61388-15</AttName>
			<Institution>Pharmacogenomics Research Network, USA</Institution>
		</Header>
		<Header title="Funding Sources">
			<AttName>CA15083-40A2</AttName>
			<Institution>Mayo Clinic Cancer Center, USA</Institution>
		</Header>
		<Header title="Funding Sources">
			<AttName>P50CA 116201-9</AttName>
			<Institution>Mayo Clinic Breast SPORE, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<StudyURLs>
		<Url name="MAYO CLINIC" url="http://mayoresearch.mayo.edu/center-for-individualized-medicine/breast-cancer-study.asp"/>
	</StudyURLs>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="GRU" longName="General Research Use"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NIGMS</DacName>
      <DacFullName>National Institute of General Medical Sciences DAC</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs001050.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>12</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs001050.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs001050.v1.p1" FileName=""/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>General Research Use</ConsentName>
        <ConsentAbbrev>GRU</ConsentAbbrev>
        <UseLimitation>Use of the data is limited only by the terms of the model Data Use Certification.
none</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
